Health Canada is inviting suggestions from stakeholders as it works on implementing a flexible approach for authorizing complex and novel health products. The regulator also draws up new clinical trial rules.

A new EU group is keeping a bird's eye view on new innovative medicinal products being brought before member states’ innovation offices, and has flagged up "emerging challenges" and "interesting cases" identified throughout 2017 that need further discussion at the level of the EU medicines network.

Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.